Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Parisi, Alessandro, Cortellini, Alessio, Cannita, Katia, Bersanelli, Melissa, Ficorella, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387689/
https://www.ncbi.nlm.nih.gov/pubmed/30881713
http://dx.doi.org/10.1155/2019/3452762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387689/
https://www.ncbi.nlm.nih.gov/pubmed/30881713
http://dx.doi.org/10.1155/2019/3452762

Ejemplares similares